| Synthetic antibody libraries focused towards peptide ligands CW Cobaugh, JC Almagro, M Pogson, B Iverson, G Georgiou Journal of molecular biology 378 (3), 622-633, 2008 | 80 | 2008 |
| Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice V Greiff, U Menzel, U Haessler, SC Cook, S Friedensohn, TA Khan, ... BMC immunology 15, 1-14, 2014 | 73 | 2014 |
| Engineering next generation proteases M Pogson, G Georgiou, BL Iverson Current opinion in biotechnology 20 (4), 390-397, 2009 | 68 | 2009 |
| Immunogenomic engineering of a plug-and-(dis) play hybridoma platform M Pogson, C Parola, WJ Kelton, P Heuberger, ST Reddy Nature communications 7 (1), 12535, 2016 | 66 | 2016 |
| Comprehensive Evaluation and Optimization of Amplicon Library Preparation Methods for High-Throughput Antibody Sequencing U Menzel, V Greiff, TA Khan, U Haessler, I Hellmann, S Friedensohn, ... PloS one 9 (5), e96727, 2014 | 66 | 2014 |
| Directed Evolution of Highly Selective Proteases by Using a Novel FACS‐Based Screen that Capitalizes on the p53 Regulator MDM2 TH Yoo, M Pogson, BL Iverson, G Georgiou ChemBioChem 13 (5), 649-653, 2012 | 36 | 2012 |
| Multi-copy genes that enhance the yield of mammalian G protein-coupled receptors in Escherichia coli G Skretas, T Makino, N Varadarajan, M Pogson, G Georgiou Metabolic engineering 14 (5), 591-602, 2012 | 32 | 2012 |
| Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange W Kelton, AC Waindok, T Pesch, M Pogson, K Ford, C Parola, ST Reddy Scientific reports 7 (1), 45775, 2017 | 27 | 2017 |
| Proteases that can distinguish among different post-translational forms of tyrosine engineered using multicolor flow cytometry N Varadarajan, M Pogson, G Georgiou, BL Iverson Journal of the American Chemical Society 131 (50), 18186-18190, 2009 | 25 | 2009 |
| Crystallographic analyses illustrate significant plasticity and efficient recoding of meganuclease target specificity R Werther, JP Hallinan, AR Lambert, K Havens, M Pogson, J Jarjour, ... Nucleic Acids Research 45 (14), 8621-8634, 2017 | 12 | 2017 |
| 100 Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML J Appelbaum, WH Leung, U Martin, K Oda, G Tampella, D Xia, J Zhang, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 2 | 2020 |
| Multivalent chimeric antigen receptor M Pogson US Patent App. 16/956,107, 2022 | 1 | 2022 |
| Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin JS Appelbaum, A Price, J Zhang, K Oda, S Sundaram, P Lewis, S Bilic, ... Blood 138, 905, 2021 | 1 | 2021 |
| Gene editing of TRAC locus utilizing megatal nucleases increases expression of transgenic TCRs delivered via lentiviral vector-mediated gene transfer MS Magee, I Diaconu, M Pogson, A Gupta, A Jensen-Smith, B Collette, ... Blood 130, 1906, 2017 | 1 | 2017 |
| Mammalian cell line for protein production and library generation S Reddy, W Kelton, C Parola, D Mason, M Pogson US Patent App. 18/329,296, 2023 | | 2023 |
| TCRa HOMING ENDONUCLEASE VARIANTS J Jarjour, M Pogson US Patent App. 18/174,165, 2023 | | 2023 |
| Mammalian cell line for protein production and library generation S Reddy, W Kelton, C Parola, D Mason, M Pogson US Patent 11,802,281, 2023 | | 2023 |
| TCRα homing endonuclease variants J Jarjour, M Pogson US Patent 11,591,582, 2023 | | 2023 |
| CD33 TARGETED IMMUNOTHERAPIES J Jarjour, M Pogson, W Leung, K Jones, W Crago, A Sanabria, A Hollands, ... US Patent App. 17/608,743, 2022 | | 2022 |
| CLL-1 TARGETED IMMUNOTHERAPIES J Jarjour, M Pogson, W Leung, L Rascon, A Sanabria, JC Timmer, ... US Patent App. 17/608,738, 2022 | | 2022 |
George GeorgiouUniversity of Texas at AustinVahvistettu sähköpostiosoite verkkotunnuksessa che.utexas.edu
